Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders
Michele Fabrazzo, Salvatore Cipolla, Alessio Camerlengo, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4530-4530
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia
Shimeng Dong, Johannes Schneider‐Thoma, Irene Bighelli, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 274, Iss. 4, pp. 917-928
Open Access | Times Cited: 22
Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy
Maria Daniela Ferreira, Joana Duarte, Francisco Veiga, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 678-678
Open Access | Times Cited: 14
Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine
Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Nicholas Aderinto, et al.
Journal of Integrative Neuroscience (2024) Vol. 23, Iss. 4, pp. 80-80
Open Access | Times Cited: 4
Cognitive improvement and prefrontal network interactions in individuals with remitted bipolar disorder after transcranial infrared laser stimulation
Douglas W. Barrett, Roger E. Davis, J E Siegel, et al.
Frontiers in Psychiatry (2025) Vol. 16
Open Access
Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report
Salvatore Cipolla, Flora Delli Carpini, Pierluigi Catapano, et al.
Clinics and Practice (2025) Vol. 15, Iss. 3, pp. 55-55
Open Access
Analyzing the Placebo Response and Identifying Influential Factors in Oral Medication Trials for Acute-Phase Schizophrenia
Jiyuan Ren, Lei Zhang, Ling Xu, et al.
Schizophrenia Bulletin (2025)
Closed Access
Non–adherence and predictors in patients with schizophrenia on second generation antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia
Melak Gedamu Beyene, Solomon Teferra, Teferi Gedif Fenta
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0314403-e0314403
Open Access
Rational Design of the First Dual Agonist at Trace Amine-Associated Receptor 1 and 5-HT2C Receptors Based on Binding Pocket Similarity for the Treatment of Schizophrenia and Alzheimer’s Disease-Related Psychosis
Jing Lu, Pengfei Yu, Yunjie Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review
Emma Y De Brabander, Kristian Kleine Schaars, Thérèse van Amelsvoort, et al.
Journal of Psychiatric Research (2024) Vol. 174, pp. 137-152
Open Access | Times Cited: 4
The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders
Octavian Vasiliu
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 10
Second-generation antipsychotics and metabolic syndrome: a role for mitochondria
Katherine R. H. Mortimer, Mohammed Zia Ul Haq Katshu, Lisa Chakrabarti
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 10
Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia
Samantha Álvarez-Herrera, Mauricio Rosel-Vales, Gilberto Pérez‐Sánchez, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 167-167
Open Access | Times Cited: 3
A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia
Panneer Selvan, Prashant Devkare, Arthik Shetty, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders
Anna Maria Auxilia, Massimiliano Buoli, Alice Caldiroli, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 314-314
Open Access | Times Cited: 8
The Janus face of antipsychotics in glial cells: Focus on glioprotection
Izaviany Schmitz, Amanda da Silva, Larissa Daniele Bobermin, et al.
Experimental Biology and Medicine (2023) Vol. 248, Iss. 22, pp. 2120-2130
Open Access | Times Cited: 8
Valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (VICTORY-S): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone
Ryotaro Kubota, Satoru Ikezawa, Hideki Oi, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 2
Combination of Two Long-Acting Antipsychotics in Schizophrenia Spectrum Disorders: A Systematic Review
Salvatore Cipolla, Pierluigi Catapano, Daniela D’Amico, et al.
Brain Sciences (2024) Vol. 14, Iss. 5, pp. 433-433
Open Access | Times Cited: 2
EFEITOS COLATERAIS DOS ANTIPSICÓTICOS DE SEGUNDA GERAÇÃO: UMA ANÁLISE COMPARATIVA ENTRE BULAS E EVIDÊNCIAS CLÍNICAS
Márcia Regina Batista, CARLA REGINA DA SILVA CORRÊA DA RONDA, SILVIA BANDIERA BORGES, et al.
(2024)
Open Access | Times Cited: 1
Reassessing mirtazapine and akathisia: A case report on its efficacy in treating severe, treatment-resistant akathisia and a review of the evidence
Madeline Chidiac, Bushra Elhusein, Niman Gajebasia
SAGE Open Medical Case Reports (2024) Vol. 12
Open Access | Times Cited: 1
Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
Joshua Caballero, Jianing Xu, Daniel B. Hall, et al.
Mental Health Clinician (2023) Vol. 13, Iss. 4, pp. 183-189
Open Access | Times Cited: 3
Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
Claudio Brasso, Silvio Bellino, Paola Bozzatello, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 22, pp. 6985-6985
Open Access | Times Cited: 3
One-Year Medication Treatment Patterns, Healthcare Resource Utilization, and Expenditures for Medicaid Patients with Schizophrenia Starting Oral Atypical Antipsychotic Medication
Kristin V. Richards, Michael Johnsrud, Christopher Zacker, et al.
Administration and Policy in Mental Health and Mental Health Services Research (2023) Vol. 51, Iss. 2, pp. 207-216
Open Access | Times Cited: 2
Navigating Schizophrenia Treatment: Balancing Symptom Relief and Long-Term Needs
Ágota Barabássy, Z.B. Dombi, Réka Csehi, et al.
IntechOpen eBooks (2024)
Open Access
Trend in the Utilization of Antipsychotics in the National Health Coverage Era in Indonesia: A Cross-Sectional Study
Julaeha Julaeha, Verra Yuliana, Josephine Paramita Ayuningtyas
Borneo Journal of Pharmacy (2024) Vol. 7, Iss. 2, pp. 224-232
Open Access
Strategies for Achieving Better Cognitive Health in Individuals with Schizophrenia Spectrum: A Focus on the Canadian Landscape: Stratégies pour atteindre une meilleure santé cognitive chez les personnes souffrant du spectre de la schizophrénie : un regard sur le paysage canadien
Martín Lepage, Synthia Guimond, Thomas J. Raedler, et al.
The Canadian Journal of Psychiatry (2024)
Closed Access
Page 1 - Next Page

Scroll to top